ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPTI Optibiotix Health Plc

18.25
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.25 17.50 19.00 18.25 18.25 18.25 144,329 07:39:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 6.43 16.64M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 18.25p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £16.64 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 6.43.

Optibiotix Health Share Discussion Threads

Showing 20851 to 20873 of 147575 messages
Chat Pages: Latest  839  838  837  836  835  834  833  832  831  830  829  828  Older
DateSubjectAuthorDiscuss
23/2/2017
10:01
Gotta a week yet wh12 and i did say "around this area" worry ye not ;))
scotty1
23/2/2017
09:48
not looking good scotty :(
whl2
23/2/2017
09:39
Without any meaningful news I think we will go lower
I see no signs of share price support via buying
Good rns'd news required
imho

judijudi
23/2/2017
09:25
Not yet scotty looking to see how the share price acts around the 50 day average.
if it holds then time to buy, if not ill wait for lower levels.
What needs remembering is that the move up from 60-80p was technically driven, nothing fundamentally has changed as the company havent delivered any market driving news since Dec 16 and we are now approaching march 17.

john henry
23/2/2017
09:19
Agree the RNSs have been hype and no substance. Thought a spin off listing was being mooted?
essential
23/2/2017
09:18
I still believe we will turn around this area and start to move back up,infact i'll do a diamond and predict we will be back up in the mid to high 70s this time next week,the only difference between mine and diamonds prediction is that mine will be correct ;))
scotty1
23/2/2017
09:16
Imho and i will email the company,the interviews and hype need to be controlled around market driving news.
The constant pumping of the share price around interviews, presentations etc isnt doing the companies any favours. Their PR certainly needs to be looked into.
Basically if you cant deliver, dont hype.
Unfortunately again today, being sold down early doors.

john henry
23/2/2017
09:12
Well get buying then JH and reverse it ;))must be good for you trading pot around here.
scotty1
23/2/2017
09:10
The buy sell ratio has got to reverse first scotty, currently around 55K sells and 26K buys.
john henry
23/2/2017
08:52
Scotty,
:)

judijudi
23/2/2017
08:20
Imo we are at the point were we will start to attract buyers once more,you know the likes of JH etc which should start and push the share price back up.Then of course they will sell at the 80p mark but hopefully we will have news on the way up which will push us through that 80p barrier once and for all.
scotty1
23/2/2017
08:15
Oh dear diamond another prediction failure from your post last Thursday if only you had predicted it would fall every day you would have remained a share guru lol.

diamond fibre - 16 Feb 2017 - 16:53:32 - 19839 of 19958 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI

Tomorrow or next week we will rise. DIAMOND

scotty1
23/2/2017
08:14
Sounds like we are getting close to launching skinbiotix.
rafboy
23/2/2017
02:25
Great find Loungact,
I like the sound of those attending.....

One Nucleus: Leadership Seminar




Rapid advances are being made in our understanding of the microbiome leading to a fundamental shift in the way we understand how microbes can be used to improve human health and wellbeing throughout life.

Microbiome – Research to Revenue is a one day event at Norwich Research Park to bring together the innovation supply chain within the microbiome sector.

The event is part of the One Nucleus Life Science Leadership Series and will highlight the interest in the sector, from the perspective of both major corporates and investors, including potential applications and market opportunities. You will also hear from new startups who will showcase the latest innovative products and services in the sector.

Programme

10:30 - Registration and Coffee

11:00 - The Science of Preventive Healthcare
Professor Ian Charles, Quadram Institute

11:15 - Session 1 – Research Trends and Market Focus

11:15 - Barry Murphy, Unilever
11:35 - Scott Parkinson, Nestle Institute of Health Sciences
Mojgan Masoodi, Nestle Institute of Health Sciences
11:55 - Mike Salter, AB Agri
12.15 - Speaker to be confirmed

12:35 - Lunch and Networking

13:45 - Keynote Address - Rt Hon George Freeman

14:00 - Session 2 – Investors View and Start-Up Showcase

This session will give the opportunity to two investors, Seventure Partners and Arix Bioscience to provide their insights on the microbiome markets and investment trends. It will be followed by three start-ups presentations.

14:00 - Denise Kelly, Seventure Partners

14:20 - Microbiome: Gut Feelings
Jonathan Tobin, Arix Bioscience

14:40 - Stephen France, SkinBiotix

15:00 - Microbiotica – Commercialising Leading Microbiome Science
Mike Romanos, Microbiotica

15:20 - Jackie Hunter, Benevolent

15:40 - Closing Remarks

15:50 - Networking

16.30 - Close


hxxp://www.onenucleus.com/onenucleus-events?id=1074

joyjoy13
23/2/2017
00:30
Skinbiotix start-up presentation. Dr Cath O'Neil is listed down to present on the 2nd March.

"Microbiome – Research to Revenue" is a one day event at Norwich Research Park to bring together the innovation supply chain within the microbiome sector. The event is part of the One Nucleus Life Science Leadership Series and will highlight the interest in the sector, from the perspective of both major corporates and investors, including potential applications and market opportunities. You will also hear from new startups who will showcase the latest innovative products and services in the sector.

hxxp://www.norwichresearchpark.com/newsandevents/events/leadershipseminarmicrobiomeresearchtorevenue.aspx

loungeact
22/2/2017
22:10
ironmom aka percy - Due to ND I cannot say. However, if you PM I'll send you a secure payment portal where you can deposit....shall we say, a donation, on receipt I'll tell you how much I have been bought for, if you promise not to cough.

wh - always naughty - my wife loves it.

elrico
22/2/2017
21:56
He's not the saviour, he's a very naughty boy!
whl2
22/2/2017
20:52
Elrico, saviour of Opti to the rescue. You really do have to counteract any & every slight against Opti don't you. How much are they paying you?
ironman22
22/2/2017
18:19
"There could be a surprising link between how people respond to a new cancer treatment and their microbiome.

Cancer immunotherapy - treatments that harness the body's immune system to fight cancer - has been gaining traction in recent years as a new approach to treating the disease.

But one of its major drawbacks is its variability: For some cancer patients, the drugs have led to remarkable remissions with few side effects. Others have tried them only to find little benefit and a lot of discomfort.

It's something researchers have been trying to understand, exploring whether there are other drugs that could be used to boost the response in some people, or if genetics could be playing an underlying role in making it more effective in others.

And they may finally be onto something. A team of researchers has recently discovered a link between people's responses to immunotherapy treatments and the microbes that live in their gut. Having a more diverse gut microbiome, they found, is linked to a better response.

The research, which will be presented at an upcoming medical conference, is the first study to make this link in people. Previous studies have however found similar results in mice."

------------------

Is this where OPTI's "potential for precision microbiome medicine" could come in useful?

parob
22/2/2017
17:39
Super food's are always on the discount so GoFigure have to natch them.
elrico
22/2/2017
17:34
Are they struggling to sell it?
More special offers than Ponden Mill!

judijudi
22/2/2017
16:28
Hopefully Christina Wood will start to earn her wages soon.
4 weeks into her role so not that long

and of course Per Rehné .. they haven'r come aboard to sit and do nothing

keep the faith

onedayrodders
22/2/2017
16:00
Even share profits have stopped promising the "big" announcements...it is a painful wait while the price dribbles lower
essential
Chat Pages: Latest  839  838  837  836  835  834  833  832  831  830  829  828  Older

Your Recent History

Delayed Upgrade Clock